Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Mannequinon Oct 10, 2024 6:49pm
64 Views
Post# 36261877

RE:RE:RE:RE:In normal market reaction the SP should have gone up

RE:RE:RE:RE:In normal market reaction the SP should have gone up

I give it 6 months  If this ship doesn't turn, we will likely see a revolving door at the top.   


PWIB123 wrote: Absolutely!  And Jones Research just downgraded THTX to a hold from a buy due to the possibility of supply disruptions for EGRIFTA, as if the stock price reflected the company value already.  Paul specifically articulated that he did not believe they would have any issues due to the amount of time they had for the FDA to approve the new batch.  His words meant nothing.  No one trusts him.

Honestly, I thought this was one of the better earnings call, however.  Better detail.  More articulate.  Gave us a set of reasonable expectations.  

 

<< Previous
Bullboard Posts
Next >>